- Randomized trial involving hospitalized SARS-CoV-2 infection patients finds that intravenous Remdesivir for 5 or 10 days showed no difference in outcome related to the duration of treatment https://www.nejm.org/doi/full/10.1056/nejmoa2015301 6 comments science
Linking pages
- Remdesivir for the Treatment of Covid-19 — Final Report | NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2007764 55 comments
- Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results | NEJM https://www.nejm.org/doi/10.1056/nejmoa2023184 54 comments
- Remdesivir for Adults With COVID-19: A Living Systematic Review for American College of Physicians Practice Points: Annals of Internal Medicine: Vol 174, No 2 https://www.acpjournals.org/doi/10.7326/m20-5752 9 comments
- Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients | NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2116846 0 comments
Linked pages
- Remdesivir for the Treatment of Covid-19 — Final Report | NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2007764 55 comments
- Home - Johns Hopkins Coronavirus Resource Center https://coronavirus.jhu.edu/ 19 comments
- A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19 | NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2001282 16 comments
- https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html 9 comments
- Clinical Characteristics of Coronavirus Disease 2019 in China | NEJM https://www.nejm.org/doi/full/10.1056/nejmoa2002032 7 comments
- Covid-19 — Navigating the Uncharted | NEJM https://www.nejm.org/doi/full/10.1056/NEJMe2002387 6 comments
Related searches:
Search whole site: site:doi.org
Search title: Remdesivir for 5 or 10 Days in Patients with Severe Covid-19 | NEJM
See how to search.